Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$2.61
-0.12-4.40%
At close: -
$2.70
0.093.45%
After Hours: May 1, 7:43 PM EDT
Comments
Loading...
Vivos Therapeutics Analyst Ratings and Price Targets | NASDAQ:VVOS | Benzinga
Vivos Therapeutics Inc has a consensus price target of $4.9 based on the ratings of 3 analysts. The high is $6.2 issued by Ascendiant Capital on April 15, 2025. The low is $2.5 issued by Ascendiant Capital on January 17, 2023. The 3 most-recent analyst ratings were released by Ascendiant Capital, Ascendiant Capital, and Alliance Global Partners on April 15, 2025, November 20, 2024, and November 19, 2024, respectively. With an average price target of $6.27 between Ascendiant Capital, Ascendiant Capital, and Alliance Global Partners, there's an implied 132.10% upside for Vivos Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Ascendiant Capital
Alliance Global Partners
Ascendiant Capital
1calculated from analyst ratings
Analyst Ratings for Vivos Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/15/2025 | Buy Now | 129.63% | Ascendiant Capital | Lucas Ward25% | $6.6 → $6.2 | Maintains | Buy | Get Alert |
| 11/20/2024 | Buy Now | 144.44% | Ascendiant Capital | Lucas Ward25% | $6.6 → $6.6 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | 122.22% | Alliance Global Partners | Scott Henry63% | $8.25 → $6 | Maintains | Buy | Get Alert |
| 08/20/2024 | Buy Now | 144.44% | Ascendiant Capital | Lucas Ward25% | $6.4 → $6.6 | Maintains | Buy | Get Alert |
| 01/17/2023 | Buy Now | -7.41% | Ascendiant Capital | Edward Woo58% | → $2.5 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Vivos Therapeutics (VVOS) stock?
The latest price target for Vivos Therapeutics (NASDAQ:VVOS) was reported by Ascendiant Capital on April 15, 2025. The analyst firm set a price target for $6.20 expecting VVOS to rise to within 12 months (a possible 129.63% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Vivos Therapeutics (VVOS)?
The latest analyst rating for Vivos Therapeutics (NASDAQ:VVOS) was provided by Ascendiant Capital, and Vivos Therapeutics maintained their buy rating.
When was the last upgrade for Vivos Therapeutics (VVOS)?
There is no last upgrade for Vivos Therapeutics
When was the last downgrade for Vivos Therapeutics (VVOS)?
There is no last downgrade for Vivos Therapeutics.
When is the next analyst rating going to be posted or updated for Vivos Therapeutics (VVOS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vivos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vivos Therapeutics was filed on April 15, 2025 so you should expect the next rating to be made available sometime around April 15, 2026.
Is the Analyst Rating Vivos Therapeutics (VVOS) correct?
While ratings are subjective and will change, the latest Vivos Therapeutics (VVOS) rating was a maintained with a price target of $6.60 to $6.20. The current price Vivos Therapeutics (VVOS) is trading at is $2.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
